Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

•Alirocumab, PCSK9, and LDL-C relationships were assessed with alirocumab 300 mg Q4W.•>80% of patients (including those on statins) achieved low-density lipoprotein cholesterol (LDL-C) goals with 300 mg Q4W.•Greater target-mediated clearance of alirocumab suggested in statin-treated patients.•Change to 150 mg Q2W more likely in statin-treated or higher baseline LDL-C patients.•Results provide further insight on alirocumab's mode of action.